Treats insomnia, characterized. Sold as Quviviq. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Daridorexant Hydrochloride (sold as Quviviq), first approved Jan 7, 2022, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Quviviq | Part D | $26.4M | +8% | 12,002 |
| A Multicenter Observational Study of Daridorexant in the Treatment of InsomniaInsomnia · Shanghai Mental Health Center | — | Not yet recruiting | Sep 29, 2026 |
| National Pregnancy Registry for Psychiatric MedicationsPregnant Women, Psychotropic Drugs · Massachusetts General Hospital | — | Recruiting | Nov 23, 2010 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
